| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
SANUWAVE Health, Inc.$9.21
+0.12 (+1.32%)
F 17Pipeline Score MedTech · Commercial
Market Cap
143.52 M
EPS
1.87
P/E Ratio
51.06 $
Value Trade
1.12 M
SEC Financials
Q1 2026Dilution Risk
Revenue
9.62 M
R&D Expenses
660.00 K
Operating CF
397.00 K
Total Assets
37.10 M
Total Liabilities
35.26 M
Equity
1.84 M
D/E Ratio
12,345
-2.28 %
Week
-13.16 %
1 Month
-32.54 %
3 Month
-47.45 %
6 Month
-99.92 %
5 Year
-100 %
All Time
Cash Data
Cash Position
10.78 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
290.73 K
52 Week Range
15.36 - 46.59
% held by Insiders
5.42 %
% held by Institutions
57.84 %
Enterprise Value
154.90 M
Total Shares
8.57 M
Short %
9.62 %
Float Shares
8.42 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 15%
Micro Cap (rank 770 of 905)
Percentile RankSANUWAVE Health, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SNWV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SNWV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SNWV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SNWV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SNWV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SNWV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SNWVSanuwave Health Updates Second Quarter 2026 Guidance
Sanuwave Health has updated its revenue guidance for Q2 2026 to between $8.5 and $9.5 million, reflecting a decline from earlier projections. The company faces market disruptions affecting sales of its Ultramist system due to reimbursement clawbacks. Despite these challenges, Sanuwave reports strong applicator sales and remains optimistic about its product pipeline.
Read more →SNWVSanuwave Announces Revenues and Financial Results for Q1 FY2026
Sanuwave Health reported Q1 2026 revenues of $9.6 million, marking a 3.1% increase from the previous year, and the highest Q1 revenues in its history. Despite a GAAP operating loss of $1.1 million, the company anticipates a 10-15% revenue growth for Q2 2026. CEO Morgan Frank noted a recovery in sales, particularly in applicator sales, and expressed optimism for continued growth throughout 2026.
Read more →SNWVSanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Sanuwave Health, Inc. reported record revenues of $13.4 million for Q4 2025, marking a 29.7% increase from the previous year. The full year revenue reached $44.1 million, up 35.0% from 2024. Despite challenges in the wound care sector, the company anticipates continued growth with guidance for Q1 2026 revenues between $9.6 and $10.3 million. The CEO highlighted the potential for their UltraMIST product amidst industry changes.
Read more →SNWVSanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Health announced preliminary revenues of $13.3 to $13.4 million for Q4 2025, marking a 29%-30% increase from Q4 2024. The full-year revenue for 2025 reached $44.3-$44.4 million, a 36% increase compared to the previous year. The company attributed its success to strategic adaptations in the evolving wound care market, positioning itself for future opportunities.
Read more →SNWVSanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Sanuwave Health, Inc. will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to January 15, 2026. The company aims to connect with investors during the event. Sanuwave focuses on developing FDA-approved wound care products and regenerative medicine technologies.
Read more →SNWVSanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
Sanuwave Health has announced the addition of its UltraMIST product line to Healogics' iSupply Group Purchasing Organization. This collaboration allows iSupply members, including various healthcare facilities, to access UltraMIST, which is expected to be rolled out by the end of 2025. The partnership aims to provide innovative wound care solutions and enhance patient care.
Read more →SNWVSanuwave Announces Q3 FY2025 Financial Results
Sanuwave Health, Inc. reported Q3 2025 revenues of $11.5 million, a 22% increase from the previous year, marking the highest quarterly revenue in its history. The gross margin improved to 77.9%, although GAAP operating income decreased to $1.5 million due to stock-based compensation costs. The company anticipates Q4 2025 revenues between $13-$14 million despite industry challenges related to reimbursement changes.
Read more →SNWVSanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
Sanuwave Health, Inc. will conduct a conference call on November 7, 2025, at 8:30 AM (ET) to discuss its Q3 2025 financial results. The call will be accessible via telephone and a link for instant access is provided. Sanuwave specializes in FDA-approved wound care products and aims to improve healing processes through its innovative technologies.
Read more →SNWVCMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610)
Sanuwave Health, Inc. announced that the final rule for the 2026 Physician Fee Schedule by CMS maintains reimbursement rates for the UltraMIST procedure (CPT code 97610) largely unchanged from 2025. The company expects slight increases in reimbursement for many providers, aligning with their prior expectations. CEO Morgan Frank emphasized the stability of these rates amidst changes in other wound care reimbursements.
Read more →SNWVSanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
Sanuwave Health announced preliminary revenues of $11.4 to $11.6 million for Q3 2025, marking the highest quarterly revenue in its history. This represents a 22-24% increase compared to Q3 2024, although it fell short of earlier guidance. The CEO noted challenges in the wound care market due to reimbursement uncertainties, leading to delayed purchasing decisions. Despite these challenges, the company recorded a significant number of system sales and plans to adjust its annual revenue guidance.
Read more →SNWVSanuwave Announces Strategic Debt Refinancing with New Credit Facility
Sanuwave Health, Inc. has announced a strategic refinancing of its debt through a new credit facility from J.P. Morgan. The $23 million term loan and $5 million revolving credit facility will help repay the existing NH Expansion debt. This move is expected to improve the company's financial position and cash flow management.
Read more →SNWVSanuwave Health to Present at Canaccord Genuity Growth Conference
Sanuwave Health, Inc. will present at the 45th Annual Canaccord Genuity Growth Conference on August 13, 2025. CEO Morgan Frank will lead the presentation and is available for one-on-one investor meetings. The company specializes in FDA-approved wound care products and regenerative medicine technologies.
Read more →SNWVSanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations
Sanuwave Health has appointed Dustin Libby as Executive Vice President of Commercial Operations. Libby, with two decades of experience in the medical device industry, previously scaled a surgical business from $15M to over $500M in revenue. His expertise is expected to enhance Sanuwave's growth in the wound care market.
Read more →Competitive Position
How SNWV ranks across every disease it competes inCompetitive Position is a premium feature
See how SNWV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial